Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company is headquartered in San Francisco, California.
| Revenue (TTM) | $36.77M |
| Gross Profit (TTM) | $-304.17M |
| EBITDA | $-353.18M |
| Operating Margin | -1042.00% |
| Return on Equity | -80.30% |
| Return on Assets | -40.10% |
| Revenue/Share (TTM) | $0.37 |
| Book Value | $3.88 |
| Price-to-Book | 6.04 |
| Price-to-Sales (TTM) | 68.17 |
| EV/Revenue | 55.63 |
| EV/EBITDA | -3.35 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -79.50% |
| Shares Outstanding | $103.78M |
| Float | $82.79M |
| % Insiders | 1.08% |
| % Institutions | 115.15% |
Volatility is currently contracting
RHHBY posts 6% constant-currency sales growth in the first half of 2026 as strong demand for key drugs offsets legacy declines, while FDA pipeline progress supports momentum.
BRISBANE, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced the closing of its previously announced global collaboration agreement with Roche to co-develop and co-commercialize bexobrutideg, following expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.
Roche wins FDA Priority Review for Gazyva in primary membranous nephropathy, with a decision due by November 2026 after positive phase III data.
Entered into global collaboration with Roche for bexobrutideg, with potential total payments of up to $2.3 billion, including $700 million upfront payment
Nurix Therapeutics (NRIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The mean of analysts' price targets for Nurix Therapeutics (NRIX) points to a 29.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
NRIX rallies on its collaboration with Roche for bexobrutideg, featuring a $700 million upfront payment and potential milestone payouts of up to $2.3 billion.
Nurix Therapeutics (NRIX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Recently, Nurix secured a partnership with Roche, which I believe has substantially derisked the stock as a whole. Similarly, this deal helps validate NRIX's bexobrutideg and its potential as a broader platform in the long term. NRIX's bexobrutideg is easily their main value driver, and after NRIX's recent equity raises and deal with Roche, it looks like they should have enough runway for the foreseeable future.
High objective response rate of 92.9% in second line patients who have progressed on a BTK inhibitor and have not received BCL2 inhibitor treatment Updated Phase 1a data further supports a median progression-free survival of 22.1 months and an objective response rate of 83% in heavily pretreated relapsed/refractory CLL/SLL patients Bexobrutideg was well tolerated with longer follow-up demonstrating a safety profile consistent with prior disclosures Responses observed across difficult-to-treat patient subgroups, including high-risk features, BTK resistance mutations and CNS involvement Data to be presented at the 2026 European Hematology Association (EHA) Congress BRISBANE, Calif., June 11, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced updated clinical data from the Company's ongoing NX-5948-301 Phase 1a/b clinical trial evaluating bexobrutideg (NX-5948), an investigational oral CNS-penetrant BTK degrader, in patients with chronic lymphocytic leukemia (CLL).
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on NRIX and any ticker you trade — then tracks every position and per-strategy win rate.
